Reference pricing of pharmaceuticals
نویسندگان
چکیده
منابع مشابه
Reference pricing of pharmaceuticals.
We consider a therapeutic market with potentially three pharmaceutical firms. Two of the firms offer horizontally differentiated brand-name drugs. One of the brand-name drugs is a new treatment under patent protection that will be introduced if the profits are sufficient to cover the entry costs. The other brand-name drug has already lost its patent and faces competition from a third firm offer...
متن کاملReference pricing with elastic demand for pharmaceuticals∗
This paper analyzes pharmaceutical producers’(of branded and generic drugs) pricing decisions in a context which combines the classical Hotelling framework (commonly adopted in the literature) with the possibility that consumers’demands are price elastic. We analyze with particular interest two commonly adopted reimbursement mechanisms: fixed percentage reimbursement (FPR) and reference pricing...
متن کاملPharmaceuticals: Reference Pricing or Price Cap Regulation?
We study the relationship between regulatory regimes and pharmaceutical firms’ pricing strategies using a unique policy experiment from Norway, which in 2003 introduced a reference price (RP) system called “index pricing” for a sub-sample of off-patent pharmaceuticals, replacing the existing price cap (PC) regulation. We estimate the effect of the reform using a product level panel dataset, cov...
متن کاملDifferential Pricing for Pharmaceuticals
The authors are responsible for the veracity of the facts stated and the views and opinions expressed in this report. Responsibility for these should not be attributed to the MIT-Zaragoza International Logistics Program, the Zaragoza Logistics Center, DFID or the policy directors and funders of these research institutes.
متن کاملReference Pricing of Pharmaceuticals: Evidence from Germany, the Netherlands and New Zealand
This paper describes three prototypical systems of therapeutic reference pricing (RP) for pharmaceuticals -Germany, the Netherlands, and New Zealand -and examines their effects on the availability of new drugs; manufacturer prices, reimbursement levels, and out-of-pocket surcharges to patients; and market shares of originator and generic products. The results differ across countries in predicta...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Health Economics
سال: 2007
ISSN: 0167-6296
DOI: 10.1016/j.jhealeco.2006.11.003